Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
3 evidence topics · 4 sources
BOND-003 induction, second induction, and maintenance schedule
“Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration in BOND-003 Cohort C and its extension
Expanded access program schedule
Dose modification
No evidence found.